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INK4a/ARF mutations accelerate
lymphomagenesis and promote
chemoresistance by disabling p53
Clemens A. Schmitt, Mila E. McCurrach, Elisa de Stanchina, Rachel R. Wallace-Brodeur,
and Scott W. Lowe1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA
The INK4a/ARF locus encodes upstream regulators of the retinoblastoma and p53 tumor suppressor gene
products. To compare the impact of these loci on tumor development and treatment response, the Eµ–myc
transgenic lymphoma model was used to generate genetically defined tumors with mutations in the
INK4a/ARF, Rb, or p53 genes. Like p53 null lymphomas, INK4a/ARF null lymphomas formed rapidly, were
highly invasive, displayed apoptotic defects, and were markedly resistant to chemotherapy in vitro and in
vivo. Furthermore, INK4a/ARF−/− lymphomas displayed reduced p53 activity despite the presence of wild-type
p53 genes. Consequently, INK4a/ARF and p53 mutations lead to aggressive tumors by disrupting overlapping
tumor suppressor functions. These data have important implications for understanding the clinical behavior of
human tumors.
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Mutations in the p53 tumor suppressor gene and at the
INK4a/ARF locus are the two most frequent genetic le-
sions identified in human tumors (for reviews, see Haber
1997; Ruas and Peters 1998). p53 is a sequence-specific
DNA-binding protein that can induce cell-cycle arrest or
apoptosis in response to pathological insults such as
DNA damage and expression of mitogenic oncogenes
(Kastan et al. 1991, 1992; Lowe and Ruley 1993; Hermek-
ing and Eick 1994; Serrano et al. 1997; for reviews, see
Giaccia and Kastan 1998; Prives 1998). As a conse-
quence, inactivation of p53 can promote oncogenic
transformation and resistance to many anticancer agents
(for reviews, see Giaccia and Kastan 1998; Prives 1998;
Wallace-Brodeur and Lowe 1999). The INK4a/ARF locus
encodes two tumor suppressors, designated p16INK4a and
p19ARF. p16INK4a is a cyclin-dependent kinase inhibitor
that acts upstream of the retinoblastoma (Rb) protein to
promote cell-cycle arrest (Serrano et al. 1993; for re-
views, see Haber 1997; Ruas and Peters 1998). p19ARF is
translated in an alternative reading frame from p16INK4a
and activates p53 by interfering with its negative regu-
lator, Mdm2 (Kamijo et al. 1998; Pomerantz et al. 1998;
Stott et al. 1998; Zhang et al. 1998; see also Tao and
Levine 1999; Weber et al. 1999; Zhang and Xiong 1999).
Consequently, INK4a/ARF mutations can disable both
the Rb and p53 tumor suppressor pathways.
Recent studies indicate that p19ARF acts as an essen-
tial intermediate in oncogene signaling to p53 (Bates et
al. 1998; de Stanchina et al. 1998; Palmero et al. 1998;
Pomerantz et al. 1998; Zindy et al. 1998; for review, see
Sherr 1998). For example, oncogenes such as E1A or c-
myc induce ARF message and protein in normal mouse
embryo fibroblasts, which correlates with their ability to
activate p53 and promote apoptosis. In contrast, these
oncogenes fail to activate p53 in ARF–null cells, and pro-
mote proliferation without substantial apoptosis (de
Stanchina et al. 1998; Zindy et al. 1998). Together, these
studies indicate that p19ARF acts as part of a p53-depen-
dent fail-safe mechanism to counter hyperproliferative
signals. Interestingly, p19ARF is not induced by DNA
damage (Kamijo et al. 1997; Stott et al. 1998) but can
cooperate with DNA damaging agents to induce apopto-
sis in oncogene expressing cells (de Stanchina et al.
1998). These studies predict that disruption of ARF, or
the INK4a/ARF locus, should cooperate with mitogenic
oncogenes during tumor development, in part, by dis-
abling p53.
p53 mutations have been associated with aggressive
cancers, poor prognosis, and drug resistance in human
patients (Schmitt and Lowe 1999; Wallace-Brodeur and
Lowe 1999). In principle, tumors with INK4a/ARF mu-
tations might also display aggressive characteristics ow-
ing to extragenic defects in the p53 pathway. To test this,
we examined the impact of INK4a/ARF mutations on
tumor development and therapy using the Eµ–myc trans-
genic mouse. These mice constitutively express c-Myc
1Corresponding author.
E-MAIL lowe@cshl.org; FAX (516) 367-8454.
2670 GENES & DEVELOPMENT 13:2670–2677 © 1999 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/99 $5.00; www.genesdev.org
 Cold Spring Harbor Laboratory Press on April 22, 2014 - Published by genesdev.cshlp.orgDownloaded from 
in the B-cell lineage and develop B-cell lymphoma with
associated leukemia (Adams et al. 1985; Adams and Cory
1991). This model was chosen for several reasons. First,
because Myc induces p19ARF and activates p53 in cul-
tured fibroblasts (Zindy et al. 1998), Eµ–myc transgenic
mice provide a relevant setting for comparing the impact
of INK4a/ARF and p53 mutations on tumor behavior.
Second, Eµ–myc lymphomas/leukemias are easily moni-
tored by lymph-node palpation or blood smears, a prop-
erty that facilitates studies examining tumor responses
to therapy. Finally, essentially pure tumor cells can be
isolated from lymph nodes and studied ex vivo or ex-
panded in genetically matched nontransgenic recipients.
The tractable nature of this model is in stark contrast to
human systems, which suffer from difficulties in obtain-
ing well-characterized and comparable clinical material.
Results
Loss of the INK4a/ARF locus accelerates
lymphomagenesis similarly to loss of p53
To generate lymphomas with defined alterations, we
crossed the Eµ–myc transgenic to mice heterozygous for
germ-line deletions in the Rb (Rb+/−), INK4a/ARF
(INK4a/ARF+/−), or p53 (p53+/−) genes (Jacks et al. 1992,
1994; Serrano et al. 1996). Of note, the INK4a/ARF+/−
animals harbor deletions that disrupt both p19ARF and
p16INK4a, thereby recapitulating the common gross dele-
tions seen in human tumors (Haber 1997; Ruas and Pe-
ters 1998). The onset of Eµ–myc lymphomas in Rb+/−
animals was variable (Fig. 1A; green, b) and only slightly
accelerated relative to that observed in the wild-type
background (hereafter referred to as control) (Fig. 1A;
black, a). In contrast, the onset of Eµ–myc lymphomas in
INK4a/ARF+/− and p53+/− animals (Fig. 1A; blue, c, and
red, d) was highly reproducible and greatly accelerated
compared with controls (P < 0.0001 each); the timing of
lymphoma development in INK4a/ARF+/− and p53+/−
mice was virtually identical. Cell surface staining con-
firmed that all lymphomas were of the B-cell lineage
(B220+; Thy1.2−), whereas the distribution of pre-B
(IgM−) and B (IgM+) was similar between the genotypes.
These data imply that p53 and products of the INK4a/
ARF locus limit Myc-induced lymphomagenesis. Con-
cordantly, Eµ–myc lymphomas arising in the p53+/− and
INK4a/ARF+/− animals invariably lost the wild-type p53
or INK4a/ARF allele (93.8% and 88.2%, respectively)
(Fig. 1B). Hence, these lymphomas were either p53-null
(p53−/−) or INK4a/ARF-null (INK4a/ARF−/−). Virtually
all control (6 out of 7), Rb+/− (4 out of 4), and INK4a/
ARF−/− (9 out of 9) tumors retained wild-type p53 as
indicated by RT–PCR and sequencing of p53 exons 4–8
(data not shown). The one p53 mutation identified
(H190R in mouse; H193R in human) corresponds to a
mutation observed in B-cell leukemias and a Burkitt’s
lymphoma (Beroud and Soussi 1998). Deletions of the
INK4a/ARF locus were noted in 20% of control and
Rb+/− tumors (4 out of 20) but never in p53−/− tumors (0
out of 10) (data not shown). In no instance did lympho-
mas arising in Rb+/− animals lose the wild-type Rb allele
(Fig. 1B), confirming that Rb loss has a minimal impact
on Myc-induced lymphomagenesis. Because Rb and
p16INK4a loss should produce similar phenotypes (Haber
1997; Ruas and Peters 1998), these data imply that
p19ARF is crucial for suppressing Myc-induced lym-
phomagenesis. The onset of Eµ–myc lymphomas is
markedly accelerated in ARF-deficient mice (Eischen et
al. 1999).
Loss of INK4a/ARF or p53 promotes lymphoma
spreading into visceral organs
INK4a/ARF−/− and p53−/− lymphomas were highly inva-
sive and infiltrated into various nonlymphoid organs. For
example, in mice bearing INK4a/ARF−/− and p53−/− lym-
phomas, we observed extensive periportal invasion and
spreading of lymphoma cell clusters throughout the liver
parenchym and massive malignant pulmonary infiltra-
tion as consolidated aggregation of large mononuclear
cells and within the distended interstitial capillaries (Fig.
Figure 1. Tumor development in Eµ–myc transgenic mice. (A)
Lymphoma incidence in Eµ–myc transgenic mice in the wild-
type (control) background (n = 65; black, a) and in mice hetero-
zygous for Rb (n = 39; green, b), INK4a/ARF (n = 41; blue, c),
p53 (n = 73; red, d), and INK4a/ARF; p53 double heterozygotes
(n = 11; orange, e). By day 70, all p53+/− and INK4a/ARF+/− mice
developed lymphoma, whereas >75% of Rb+/− and control mice
remained tumor free. (B) Matched normal (N) and tumor (T)
DNA were isolated from tail and lymph nodes and analyzed by
allele-specific PCR for the targeted gene [(m) mutated allele; (wt)
wild-type allele]. Shown are results from five Eµ–myc trans-
genic mice in each genetic background. Note that tumors aris-
ing in the INK4a/ARF+/−; p53+/− double heterozygotes invari-
ably lost the wild-type p53 allele but never the INK4a/ARF
allele.
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2). Also, neoplastic cells accumulated in the submucosa
of the urinary bladder, within the kidneys, in the serosal
and mesenteric surfaces of the gasterointestinal tract,
and along the meninges. In contrast, tumors in mice
bearing control or Rb+/− lymphomas showed little sys-
temic infiltration or remained localized to the lymph
nodes and blood compartment despite a similarly large
tumor burden. The invasive behavior of INK4a/ARF−/−
and p53−/− tumors was reproduced following transplan-
tation of the tumors into syngenic recipients (data not
shown) and is indicative of a highly aggressive disease.
INK4a/ARF−/− lymphomas show an apoptotic defect
but no genomic instability
p53 mutations can decrease cell death, increase prolif-
eration, and produce chromosomal instability depending
on context (Schmitt and Lowe 1999; Wallace-Brodeur
and Lowe 1999). To determine the impact of INK4a/ARF
and p53 mutations on these characteristics, we exam-
ined apoptosis, mitotic index, and DNA content in con-
trol, INK4a/ARF−/− and p53−/− lymphomas. As revealed
by histological staining and TUNEL (terminal deoxy-
nucleotidyl transferase dUTP nick end labeling), control
lymphomas contained large numbers of apoptotic cells
that clustered (Fig. 3A). Apoptosis was much reduced in
INK4a/ARF−/− or p53−/− lymphomas, and the apoptotic
cells that appeared were isolated. Furthermore, primary
INK4a/ARF−/− and p53−/− lymphoma cells explanted
into culture survived much better than controls (Fig. 3B).
The mitotic index (Fig. 3C) and S-phase fraction (Fig. 3D)
of all lymphoma types analyzed were similar, implying
that INK4a/ARF or p53 mutations did not affect the pro-
liferation rate. DNA content analysis revealed one no-
table difference: Whereas most of the p53−/− tumors
were aneuploid (10 out of 12), most control and INK4a/
ARF−/− tumors remained diploid (13 out of 14 and 13 out
of 14, respectively) (Fig. 3D). Together, these data dem-
onstrate that highly aggressive lymphomas can occur in
the absence of chromosomal instability and imply that
the aggressive nature of INK4a/ARF−/− and p53−/− lym-
phomas is due to an apoptotic defect.
INK4a/ARF mutations compromise p53 function
in vivo
The remarkable similarities between INK4a/ARF−/− and
p53−/− lymphomas suggest that these mutations disrupt
Figure 2. Invasiveness of Eµ–myc lymphomas in liver and lung
(H.E. staining, 200×). Representative examples of control, Rb+/−,
INK4a/ARF−/−, and p53−/− lymphomas are shown. Note the ma-
lignant embolus in the pulmonary vessel of the control—none-
theless, the lung itself remained tumor free. The relative con-
gestion of the Rb+/− lung is a postmortem artifact.
Figure 3. Analysis of apoptosis, proliferation, and chromosom-
al stability in Eµ–myc lymphomas. (A) Apoptosis in situ (lymph
nodes) was visualized by HE staining and TUNEL. The reduced
apoptotic rate observed in INK4a/ARF−/− tumors is consistent
with a similar defect observed in the ocular lens of Rb−/−;
INK4a/ARF−/− embryos (Pomerantz et al. 1998). (B) Viability of
control (d), INK4a/ARF−/− (s), and p53−/− (j) lymphoma cells
as measured by trypan blue exclusion after explanting onto
feeder cells. (C) Proliferation as estimated by the percentage of
mitotic figures in HE-stained lymphoma sections. (D) DNA
content analysis of primary Eµ–myc lymphoma. The S-phase
fractions of control (30.25% ± 8.31, n = 9) and INK4a/ARF−/−
(29.98% ± 6.39, n = 10) were virtually identical, whereas sub-
G1 fractions of control (3.26% ± 3.17) and INK4a/ARF−/−
(0.30% ± 0.56) lymphomas were significantly different
(P = 0.0097). Note that sub-G1 assessment recognizes only late
apoptotic cells and gives lower estimates than TUNEL. Calcu-
lations of S-phase and sub-G1 fraction in p53−/− lymphomas
were impossible due to aneuploidy. Representative profiles are
shown. Note that low frequency of aneuploidy in control and
INK4a/ARF−/− lymphomas (1 of 14 and 1 of 14, respectively) is
consistent with the overall p53 mutation rate we observed in
these tumors.
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overlapping tumor suppressor functions. In agreement,
Eµ–myc lymphomas arising in mice heterozygous for
both genes (INK4a/ARF+/−; p53+/−) were detected at the
same time as lymphomas in the INK4a/ARF+/− and
p53+/− animals (50th percentile = 38 vs. 38 vs. 36 days to
onset, respectively) (Fig. 1A; orange, e) and never dis-
played coincident loss of both wild-type INK4a/ARF and
p53 alleles (data not shown). Therefore, inactivation of
both loci produces no additional advantage to Eµ–myc
lymphomas. In cultured fibroblasts, Myc activates p53 in
an ARF-dependent manner (Zindy et al. 1998). Similarly,
control Eµ–myc lymphomas displayed a variable but
consistent increase in p53 levels and activity (as mea-
sured by expression of the p53 target p21) compared with
normal splenocytes (Fig. 4A, cf. N with control). This
increase appeared dependent on the INK4a/ARF locus,
because INK4a/ARF−/− tumors displayed only a modest
induction of p53 and virtually no increase in p21 (Fig.
4A). This implies that INK4a/ARF mutations can accel-
erate tumor progression and impair apoptosis by com-
promising p53 function.
INK4a/ARF mutations reduce p53 activation
following chemotherapy
The fact that p19ARF can cooperate with DNA-damaging
agents to induce p53 and apoptosis raises the possibility
that INK4a/ARF mutations might compromise cancer
therapy (de Stanchina et al. 1998). To test this, we ex-
amined the impact of INK4a/ARF or p53 mutations on
drug-induced responses in reconstituted lymphomas or
following short-term culture. Reconstituted lymphomas
were produced following intravenous injection of pri-
mary lymphoma cells into syngenic (nontransgenic)
recipients, thereby eliminating the possibility that sec-
ondary malignancies might complicate scoring tumor
responses. Importantly, these lymphomas were histo-
pathologically identical to their respective primary tu-
mors (data not shown). In control lymphomas, p53 and
p21 levels were dramatically increased 4 hr after treat-
ment with cyclophosphamide (CTX), an alkylating agent
used to treat human leukemia and lymphoma (Fig. 4B).
p53 and p21 levels also increased in INK4a/ARF−/− lym-
phomas, although this response was consistently re-
duced compared with controls. Therefore, in Eµ–myc
lymphoma cells, INK4a/ARF mutations can reduce p53
activation by a DNA damaging agent.
INK4a/ARF mutations affect the short-term response
to anticancer treatment
Loss of either INK4a/ARF or p53 had a profound effect
on drug-induced cell death in vitro and in vivo. In short-
term cultures, INK4a/ARF−/− or p53−/− lymphomas dis-
played a marked resistance to mafosphamide (a CTX
analog active in vitro) (Fig. 5A). In peripheral blood, con-
trol animals harboring associated leukemias displayed a
nearly 100-fold reduction in the white blood cell count
(WBC) within 4 hr of CTX therapy, which coincided with
a 6- to 10-fold accumulation of apoptotic cells (Fig. 5B,C).
In contrast, INK4a/ARF−/− and p53−/− leukemias took
12–24 hr to achieve a similar reduction. Apoptosis was
not detectable, perhaps because the slow death rate al-
lowed clearance of apoptotic cells before they could ac-
cumulate. In lymph nodes, control lymphomas displayed
massive apoptosis 5 hr after CTX therapy, whereas the
INK4a/ARF−/− and p53−/− lymphomas displayed sub-
stantially fewer dying cells (Fig. 5D).
INK4a/ARF mutations impair the long-term response
to anticancer treatment
The ultimate determinant of drug-induced cell kill is
tumor regression and the duration of remission. To as-
sess long-term responses, animals harboring control,
INK4a/ARF−/−, or p53−/− lymphomas were treated with
CTX and monitored for remission and relapse by lymph
node palpation and WBC. Control lymphomas responded
extremely well to CTX treatment, and >70% remained
in remission during the 100-day observation period (Fig.
6; black, a). In stark contrast, INK4a/ARF−/−- and p53−/−-
null tumors displayed an extremely poor response to
CTX therapy: Despite initial responses, only 1 out of 14
p53−/− and 4 out of 35 INK4a/ARF−/− lymphomas re-
mained in remission. p53−/− tumors (Fig. 6; red, c) were
the most relapse prone (50th percentile = 20 days in re-
mission, P < 0.0001 compared with control), although
the defect in the INK4a/ARF−/− response (Fig. 6; blue, b)
was also highly significant (50th percentile = 28 days in
Figure 4. p53 levels and activity in untreated and CTX-treated
Eµ–myc lymphomas. (A) Control (three independent tumors),
INK4a/ARF−/− (four independent tumors), and p53−/− lym-
phoma lysates were probed against p53 and the p53 downstream
target p21, reflecting p53’s activity. Normal splenocytes (N)
from nontransgenic mice were used for comparison. Tubulin
(Tub) was used to verify protein loading. (B) Control, INK4a/
ARF−/−, and p53−/− lymphoma cells were isolated from lymph
nodes of untreated animals (NT) or 4 hr after CTX treatment (T1
and T2) and analyzed as above. For each tumor type, T1 and T2
were derived from separate primary tumors, whereas NT and T1
represent reconstituted lymphomas derived from the same pri-
mary tumor.
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remission, P = 0.0053 compared with control). The re-
sponse of INK4a/ARF+/−;p53−/− double-mutant lympho-
mas (Fig. 6; orange, d) was virtually identical to the
p53−/− tumors (50th percentile = 20 days in remission),
and the relapsed tumors never displayed loss of the wild-
type INK4a/ARF allele (data not shown). Therefore, al-
though INK4a/ARF mutations promote chemoresis-
tance in the presence of wild-type p53 genes, they confer
no additional survival advantage once p53 is mutated.
These data demonstrate that INK4a/ARF mutations can
compromise therapy, at least in part, by disabling p53.
Discussion
By comparing the properties of Myc-induced lymphomas
in several genetic backgrounds, we provide compelling
evidence that INK4a/ARF deletions can impact tumor
development and anticancer therapy by compromising
p53 function. Like p53−/− tumors, INK4a/ARF−/− lym-
phomas formed rapidly, were highly invasive, displayed
apoptotic defects, and were markedly resistant to che-
motherapy. Furthermore, INK4a/ARF−/− lymphomas
displayed attenuated p53 activity despite the presence of
wild-type p53 genes. The profound impact of INK4a/
ARF and p53 mutations on Myc-induced lymphomagen-
esis indicates that the ARF–p53 pathway contributes to
oncogene-induced cell death in developing tumors and
underscores the importance of this fail-safe mechanism
in tumor suppression (also see Eischen et al. 1999; Jacobs
et al. 1999). Furthermore, that INK4a/ARF mutations
can compromise drug-induced cell death in Eµ–myc lym-
phomas implies that cooperative effects between onco-
genes (in part via ARF) and DNA damage contribute to
the remarkable drug sensitivity of some tumors.
The only substantial difference between INK4a/
ARF−/− and p53−/− lymphomas was that the INK4a/
ARF−/− lymphomas remained diploid, whereas the
p53−/− lymphomas were aneuploid. This pattern is remi-
niscent of ARF−/− and p53−/− fibroblasts (Kamijo et al.
1997) and implies that p19ARF does not control the p53
functions involved in maintaining chromosome stabil-
ity. Although we have not analyzed the secondary
changes arising in INK4a/ARF−/− tumors in detail, these
data argue that invasive, chemoresistant lymphomas can
arise in the absence of substantial chromosomal insta-
Figure 6. INK4a/ARF, p53, and long-term response to chemo-
therapy. Nontransgenic mice harboring reconstituted control
(n = 60; black, a), INK4a/ARF−/− (n = 35; blue, b), p53−/− (n = 14;
red, c), and INK4a/ARF+/−; p53−/− (n = 15; orange, d) lymphomas
were treated with CTX and monitored for tumor regression and
relapse. Importantly, CTX is not affected by classic multidrug
resistance mechanisms that might complicate drug delivery.
Tumor shrinkage to nonpalpability within 6 days after treat-
ment is considered ‘remission’ and creates the tumor-free popu-
lation at time 0. Relapse was defined by recurrent palpable
lymph node enlargement. Values were plotted in Kaplan-Meier
survival curve format and presented as percentage of mice in
remission over the time post-therapy. Note that the overall rate
of treatment failure in control lymphomas (~ 25%–30%) is con-
sistent with the combined frequency of INK4a/ARF and p53
mutations we observe in these tumors.
Figure 5. INK4a/ARF, p53, and short-term response to chemo-
therapy. (A) Explanted control (d), INK4a/ARF−/− (s), and
p53−/− (j) lymphoma cells were treated with mafosphamide
(MAF). Viability was analyzed after 24 hr by trypan blue exclu-
sion; each value was normalized to untreated controls and rep-
resents the mean ± S.D. of two independently derived tumors
reproduced in duplicate. (B) Leukemic mice were treated with
CTX, and blood samples were taken at the indicated times. Each
WBC is relative to its pretreatment value and represents the
mean ± S.D. of three independent leukemias. Symbols are as in
A. (C) Same as in B, except that blood samples were ethanol-
fixed and stained with the DNA fluorochrome DAPI to visual-
ize the chromatin condensation characteristic of apoptotic
cells. Each value reflects the percentage of cells with apoptotic
morphology (of 200 cells counted) and represents the
mean ± S.D. of three independent leukemias. Symbols are as in
A. (D) HE staining and TUNEL of lymph nodes harboring con-
trol, INK4a/ARF−/−, and p53−/− lymphomas 5 hr after CTX
treatment.
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bility. In turn, because INK4a/ARF mutations disable
p53, the chromosomal instability observed in p53−/−
lymphomas appears dispensable for the aggressive be-
havior of these tumors.
More likely, the increased invasiveness and drug resis-
tance of INK4a/ARF−/− and p53−/− lymphomas arises
from an apoptotic defect. INK4a/ARF−/− and p53−/− lym-
phomas displayed decreased apoptosis in situ and ex vivo
(see Figs. 3 and 5), whereas there was no obvious rela-
tionship between tumor-cell genotype and proliferation,
as measured by mitotic index in vivo, DNA content
analysis ex vivo, and proliferation properties in vitro (see
Fig. 3; data not shown). These results stand in contrast to
an earlier report indicating that p53-null Eµ–myc lym-
phomas do not display an apoptotic defect (Hsu et al.
1995). Although we cannot explain this discrepancy, it is
worth noting that disruption of apoptosis using a bcl-2
transgene is sufficient to accelerate Myc-induced tu-
morigenesis (Strasser et al. 1990). Moreover, ectopic ex-
pression of bcl-2 in the control lymphoma cells used in
this study has no effect on proliferation but renders these
cells highly invasive and chemoresistant following
transplantation into syngenic mice (C.A. Schmitt and
S.W. Lowe, unpubl.).
Although Eµ–myc lymphomas harboring INK4a/ARF
or p53 mutations are defective in CTX-induced cell
death, CTX therapy induces complete remissions irre-
spective of p53 status. We suggest that the p53-indepen-
dent death is due to apoptosis, because Eµ–myc lympho-
mas expressing Bcl-2 are completely nonresponsive to
CTX therapy at the maximally tolerated dose (C.A.
Schmitt and S.W. Lowe, unpubl.). In contrast to CTX,
doxorubicin fails to induce remissions in p53−/− lympho-
mas, although high doses induce p53-independent apop-
tosis in vitro (R.R. Wallace-Brodeur, M.E. McCurrach,
and S.W. Lowe, unpubl.). Thus, the ability to achieve
p53-independent killing depends on agent and dose.
These data are consistent with the view that p53 is not
an essential component of the apoptotic machinery but,
rather, increases the probability that these agents trigger
cell death (Lowe et al. 1993). In Eµ–myc lymphomas, this
increased propensity for apoptosis can determine tumor
cure or relapse.
Our data have important implications for the under-
standing of the clinical behavior of human tumors. First,
they provide compelling evidence that disruption of
apoptosis during tumor development can simulta-
neously select for chemoresistant cells. This pattern of
coselection may explain why some tumors are de novo
‘resistant’ despite having no prior exposure to drug and
why it is difficult to separate the impact of p53 muta-
tions on treatment sensitivity from its contribution to
overall patient prognosis. Second, our results demon-
strate that tumors with extragenic mutations in the p53
pathway can display properties of p53 mutant tumors.
This fundamental point is crucial for interpreting studies
relating p53 mutations to clinical parameters in human
patients, which typically classify tumors strictly by p53
gene or protein status. Our data imply that a substantial
number of p53 ‘normal’ tumors would be misclassified
by this approach (e.g., those harboring ARF mutations)
and may explain why some studies fail to correlate p53
mutations with adverse clinical features (for review, see
Brown and Wouters 1999).
This study provides the first evidence that INK4a/
ARF mutations can have a negative impact on the out-
come of cancer therapy and suggests that this defect
arises from the failure of drugs to appropriately activate
p53. Consequently, these data predict that disruption of
the INK4a/ARF locus will contribute to chemoresis-
tance in human tumors. As for p53 mutations, it seems
likely that the overall impact of INK4a/ARF disruption
on chemoresistance will depend on additional factors,
such as tissue type, agent, and the mutational back-
ground of the tumor (for review, see Wallace-Brodeur and
Lowe 1999; also see Bunz et al. 1999). However, it is
noteworthy that p53 mutations are strongly associated
with highly aggressive tumors and chemoresistance in
human hematologic malignancies (e.g., see Elrouby et al.
1993; Diccianni et al. 1994; Fan et al. 1994; Wattel et al.
1994; Wilson et al. 1997), indicating that Eµ–myc lym-
phomas can recapitulate the behavior of human tumors.
Therefore, we anticipate that this model will be useful
for testing strategies to counter p53 and INK4a/ARF mu-
tations in hematologic malignancies and other cancers.
Materials and methods
Mouse strains and tumor monitoring
All animal protocols used in this study were approved by the
Cold Spring Harbor Laboratory Animal Care and Use Commit-
tee. Eµ–myc transgenic mice (C57BL/6 inbred strain) and Rb−/−,
INK4a/ARF−/−, and p53−/− mice (C57BL/6 × 129/sv) were
crossed, and the offspring was genotyped by allele-specific PCR
(Jacks et al. 1992, 1994; Serrano et al. 1996). Transgenic mice of
the F1 generation (pooled from the different crosses) or trans-
genics being heterozygous for the named loci were monitored
twice a week by palpation of the prescapular and cervical lymph
nodes. Enlargements of at least 5 mm in the longest diameter
were considered ‘well palpable’ and reflect malignant disease.
For determining white blood cell status, blood smears and 20 µl
of peripheral blood were obtained by tail artery bleeding. After
ammoniumchloride hemolysis of the PBS-diluted and K3–
EDTA-anticoagulized blood sample, white blood cells were
counted in a hemocytometer. Blood smears were fixed and
stained using the Leukostat kit (Fisher Diagnostics). Mice hav-
ing WBC > 3 × 105/µl and being positive for lymphoblastic cells
in the blood stream were considered ‘leukemic’.
Histopathology
Animals harboring control, Rb+/−, INK4a/ARF−/−, and p53−/−
lymphomas were sacrificed when prescapular lymph nodes
reached a well-palpable size. Paraffin-embedded (7 µm), 4% neu-
tral-buffered formalin-fixed tissue sections derived from lymph
nodes and lung and liver specimens were stained with hema-
toxyilin–eosin (HE) to evaluate apoptotic nuclear morphology
and invasiveness of lymphoma cells into visceral organs.
Lymphoma characterization, LOH analysis,
and RT–PCR sequencing
After CO2 euthanasia, lymph nodes were dissected, minced in
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PBS, and filtered through a 35-µm nylon mesh. Single cell sus-
pensions of freshly harvested lymphomas were immunopheno-
typed by flow cytometry using antibodies directed against Thy-
1.2, B220, and IgM (Pharmingen). Pre-B-cell lymphomas are
Thy-1.2−, B220+, and IgM−, whereas mature B-cell lymphomas
are Thy-1.2−, B220+, and IgM+. To determine the mutational
status of various genes, primary lymphoma cells were subjected
to short-term culturing to eliminate normal cell contamination.
Loss of the remaining wild-type allele [loss of heterozygosity
(LOH)] in tumors arising in mice being heterozygous for an in-
dicated tumor suppressor locus was detected by allele-specific
PCR (Jacks et al. 1992, 1994; Serrano et al. 1996). Exons 4–8 of
the p53 gene were sequenced by dye termination in an auto-
mated sequencer (Perkin-Elmer) after reverse transcription (Su-
perScript, GIBCO BRL) and PCR amplification of lymphoma
cell total RNA. Finally, the gross integrity of the INK4a/ARF
locus was assessed using PCR of exons 1b and exon 2 in a
multiplex PCR reaction harboring primers to a positive control.
Lymphoma cell culture and in vitro treatment
Single cell suspensions of freshly extracted lymphoma cells (see
above) were plated on irradiated (30 Gy) feeder layer (106 NIH-
3T3 cells/2.4-cm plate) in 45% Iscove’s modified Eagle me-
dium, 45% Dulbecco’s minimal essential medium, 10% fetal
bovine serum, 100 U/ml penicillin and streptomycin, 4 mM
L-glutamine, and 25 µM 2-mercaptoethanol. For in vitro drug
assays, mafosphamide (cyclohexylammonium salt, a CTX ana-
log active in vitro; a generous gift from Asta Medica, Germany)
was added at 0, 0.3, 3, and 30 µg/ml, and viability was measured
(see below) 24 hr later.
Assessment of viability, cell-cycle parameters, and apoptosis
Viability of short-term cultured lymphoma cells was analyzed
by trypan blue dye exclusion. For analysis of ploidy, apoptosis
(as percentage of cells in sub-G1 peak), and proliferation (as per-
centage of viable cells in S phase), 106 ethanol-fixed lymphoma
cells were incubated for 30 min at room temperature in 1 ml of
DNA staining solution (200 µg of propidium iodide and 2 mg of
RNase in 10 ml of PBS), and DNA content was measured at 488
nm in a flow cytometer (FACScalibur, Becton Dickinson). In
situ proliferation was estimated by counting of mitotic figures
(cells in anaphase or telophase) relative to cell number in HE-
stained lymphoma sections (four samples each genotype, seven
different fields, 200 cells each). In situ apoptosis was visualized
in lymphoma sections by HE staining and a fluorescence-based
TUNEL assay. TUNEL assays were performed in accordance to
the manufacturer’s protocol (Boehringer Mannheim). Leuke-
mias were analyzed for apoptotic nuclear morphology by fluo-
rescence microscopy after ethanol fixation and DAPI (48,6-Di-
amidino-2-phenylindole) staining of peripheral blood samples.
Western blotting analysis
Whole-cell lymphoma cell or normal splenocyte lysates were
generated by lysing of extracted cells in SDS sample buffer (60
mM Tris-HCl at pH 6.8, 10% glycerol, 2% SDS, and 5% 2-mer-
captoethanol). Samples corresponding to 60 µg of protein (Bio-
Rad Bradford protein assay) were separated on a SDS–polyacryl-
amide gel and transferred to Immobilon-P membranes (Milli-
pore). p53 was detected using the polyclonal antibody CM5
(Novocastra, 1:2000 dilution), p21 using the polyclonal anti-
body C-19 (Santa Cruz, 1:500 dilution), and a-tubulin using the
monoclonal antibody B-5-1-2 (Sigma, 1:2000 dilution). Protein
detection was visualized by ECL (Amersham) or Supersignal
(Pierce).
Lymphoma reconstitution and in vivo treatment
Immediately after extraction, 106 lymphoma cells in 100 µl of
PBS were reconstituted by tail vein injection into genetically
matched, nontransgenic recipient mice (two mice per individual
lymphoma sample) to monitor response to treatment. Tumors
derived from the INK4a/ARF+/− and p53+/− backgrounds were
reconstituted in C57BL/6 × 129/sv mice (Jackson Laboratories).
CTX was applied as a single 300-mg/kg dose i.p. when arising
tumors became well palpable.
Statistical evaluation
Tumor onset data reflect the time between birth and first-time
palpability of enlarged lymph nodes; treatment response data
reflect the time between remission and relapse as first-time
palpability of a recurrent lymph node enlargement. Individual
time values were plotted in the Kaplan-Meier population–event–
time course format and compared using the log-rank (Mantel-
Cox) test. Comparisons of means and standard deviations (S.D.)
were performed using the unpaired t-test. Ploidy, cell cycle dis-
tribution, and sub-G1 content were analyzed using the ModFit
LT 2.0 software.
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